article thumbnail

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

BioPharma Drive: Drug Pricing

The company also has $1 billion in senior notes coming due in 2027. The company believes sales in ambulatory patients are likely to annualize at a minimum of $500 million annually through 2027. Bloomberg Ex-Pfizer Doctor Tells Congress He Didn’t Delay Covid Shot Data The Washington Post Can new blood tests really detect cancer early?

article thumbnail

Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not

FDA Law Blog: Biosimilars

The regulated cannabis marketplace brings in billions of dollars in revenue into state and federal governments, with predictions that cannabis sales will exceed $53 billion by 2027. Studies have found that marijuana access has public health benefits by reducing the rates of opioid use and opioid deaths.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS

The Pharma Data

down 21%, driven by a negative impact from the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventative health purposes, as well as the loss of patent protection in the U.S. RE47,739 for Ibrance by more than four years until March 2027. Hospital products, which grew 10% operationally to $2.3

article thumbnail

Abelacimab: the next frontier in safer anticoagulation therapy 

Drug Target Review

These studies, anticipated to complete in 2027, could open doors for abelacimab’s approval in this indication. “We anticipate ASTER will complete in early 2027 and could form the basis for approval in the treatment and prevention of venous thrombotic events in patients with cancer,” Bloomfield said. .